Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Known human immunodeficiency virus or active hepatitis C viral infection
Known history of human immunodeficiency virus infection (HIV) or hepatitis C or active hepatitis B infection, unless the patient was diagnosed >10 years prior to enrollment and no evidence of active liver disease.
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Known human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infection
New York Heart Association (NYHA) stage III/IV congestive heart failure, arrhythmias not adequately controlled, active infections, or other significant co-morbidities [e.g. active central nervous system metastases and/or carcinomatous meningitis, active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C.
Known ongoing or active systemic infection, active hepatitis B or C virus infection
No known human immunodeficiency virus (HIV) positive, or active hepatitis infection
Known active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Patients who have active infection including known human immunodeficiency virus (HIV) infection
Active hepatitis or human immunodeficiency virus infection
Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded
PHASE II EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics with 2 weeks of study enrollment
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection.
Ongoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection.
Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
Known active human immunodeficiency virus (HIV) or hepatitis B or C infection
Known human immunodeficiency virus or active hepatitis B or C viral infection
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Has active human immunodeficiency virus infection that is uncontrolled (increasing plasma HIV RNA viral load) with medication, or has an active hepatitis B or C infection
Known infection caused by human immunodeficiency virus (HIV) or active hepatitis B or C
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
Known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment; patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known or active human immunodeficiency virus (HIV) infection or active hepatitis B or C viral infection
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus (testing not required prior to enrollment)\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection.
Patients with a known chronic immunocompromised state, human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment
Known to have acute or chronic active hepatitis B infection, hepatitis C infection, or known to have human immunodeficiency virus (HIV) infection
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection
Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus
Known history of human immunodeficiency virus infection or an active hepatitis B or C virus infection (exception: this criteria does not apply to patients with cervical/anal tumours enrolling in Cohort 6)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required)
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Ongoing or active known infection, including human immunodeficiency virus (HIV) infection
Known active acute or chronic infection including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis
Known human immunodeficiency virus (HIV) infection or active hepatitis A, B or C
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Ongoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Active hepatitis A, B, or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positivity
Known ongoing or known active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Active and uncontrolled infection including but not limited to known infection with human immunodeficiency virus (HIV), active hepatitis B, or hepatitis C
Active infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy, human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Known positive for human immunodeficiency virus-1 (HIV-1), or active infection with hepatitis-B or -C
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence\r\nof cirrhosis AND the patient’s liver function tests fall within the parameters set
Human immunodeficiency virus (HIV) infection, active hepatitis B or C infection, or evidence of liver cirrhosis
A known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment
History of human immunodeficiency virus (HIV), or known active hepatitis B or C infection.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection.
Known positive test result for human immunodeficiency virus or active hepatitis B or C virus infection
Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection based on positive tests during Screening
Chronic hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive, that might affect host immunity
Ongoing, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
RENAL & BLADDER: Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection
Active systemic infection requiring treatment, including any human immunodeficiency virus (HIV) infection or toxoplasmosis
Evidence of any of the following conditions per subject self-report or medical chart review\r\n* Any prior invasive malignancy within 5 years of enrollment that may affect outcome of study\r\n* Any non-invasive malignancy not treated with curative intent or with known active disease within 5 years before enrollment that may affect outcome of study\r\n* Major surgery or significant traumatic injury occurring within 4 weeks before enrollment\r\n* Active infection with hepatitis B virus or hepatitis C virus\r\n* Known infection with human immunodeficiency virus (HIV)\r\n* Active infection requiring IV anti-infective therapy
Patients with known active hepatitis B or C or human immunodeficiency virus (HIV) infection or with history of tuberculosis
Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Known active human immunodeficiency virus (HIV) or hepatitis A, B, or C virus infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set above
Ongoing or active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known active hepatitis B infection, known active hepatitis C infection, or known human immunodeficiency virus (HIV) carrier
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness will be excluded from the study; HIV-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) infection or known history of active hepatitis B or C infection
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness
Known infection with human immunodeficiency virus, or active hepatitis B or C, or other active clinically relevant liver disease.
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Known history of human immunodeficiency virus (HIV) seropositivity, acute or chronic active hepatitis B or C infection, or other serious chronic infection requiring ongoing treatment
Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.
Has evidence of interstitial lung disease, active non-infectious pneumonitis, a known additional malignancy that is progressing or requires active treatment, an active infection requiring intravenous systemic therapy, an active autoimmune disease that has required systemic therapy, a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infection
Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Known active hepatitis B or C, or human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;
Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.
Active viral hepatitis or active human immunodeficiency virus infection
Patient has a known history of human immunodeficiency virus (HIV) (testing not mandatory), active hepatitis B or C infection
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (B or C)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Patients with active infections including uncontrolled human immunodeficiency virus (HIV) infection, active hepatitis B, C, or any other symptomatic systemic infection requiring active therapy will be excluded from study
Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for hepatitis virus)
Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, or life-threatening illnesses unrelated to cancer.
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection (including undetectable viral loads while on antiviral therapy) and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Active infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus.
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
The participant has active infection requiring systemic therapy, including active tuberculosis or known history of infection with the human immunodeficiency virus (HIV 1/2 antibodies), or hepatitis B (e.g., HBsAg reactive) and/or C virus (e.g., HCV RNA [qualitative] is detected).
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus.
Clinically active infection as judged by the treating investigator (? Grade 2 by CTCAE v4) including known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Known active uncontrolled human immunodeficiency virus (HIV) or hepatitis C infection
Comorbidities or prior conditions:\r\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\r\n* Prior organ transplantation including allogenic stem-cell transplantation\r\n* Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy\r\n* Known history of active TB (Tuberculosis)\r\n* Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome\r\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening or positive serologies indicating prior infection\r\n* Active infection requiring systemic therapy\r\n* Has evidence of interstitial lung disease or active, non-infectious pneumonitis\r\n* Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Known human immunodeficiency virus (HIV) or active hepatitis B or C viral infection
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Active hepatitis B or C virus infection, or known human immunodeficiency virus(HIV) positive
A known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Known human immunodeficiency virus (HIV) or active hepatitis B or C infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Known active infection, or on antiretroviral therapy for human immunodeficiency virus (HIV) disease or positive test for chronic hepatitis B or C infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set in inclusion criteria number 8c, “hepatic function”
Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Patients with known active viral hepatitis or known human immunodeficiency virus (HIV) infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set
Known active infection with human immunodeficiency virus (HIV), hepatitis B or C
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Has known, previously diagnosed human immunodeficiency virus infection or active chronic hepatitis B or C.
Ongoing or active systemic infection, history of hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.
Known human immunodeficiency virus (HIV) or active hepatitis B or C infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Known active human immunodeficiency virus (HIV) infection, hepatitis B or C
Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Acute hepatitis, known human immunodeficiency virus (HIV), or active uncontrolled infection
No infection with human immunodeficiency virus (HIV) and no active infection with hepatitis B and no active or chronic infection with hepatitis C
No human immunodeficiency virus (HIV) infection, active hepatitis B infection, or active hepatitis C infection
Current evidence or previous medical history of (ie, any absolute risk of latent infection) hepatitis B or C, any active hepatitis, or human immunodeficiency virus (HIV) infection. Active clinically serious infections > CTCAE Grade 2.
Ongoing or active known infection, including human immunodeficiency virus (HIV) infection or bleeding
Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection
Known history of human immunodeficiency virus (HIV) or active hepatitis C Virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Human immunodeficiency virus (HIV) infection; active hepatitis B infection; active hepatitis C infection
Active infection requiring systemic therapy, known human immunodeficiency virus infection, or positive test for hepatitis B active infection or hepatitis C active infection.
Known active infection with human immunodeficiency virus (HIV), hepatitis A, B, or C
Known positive status for human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection
Known active hepatitis B/C or HIV (human immunodeficiency virus) infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
